Corrigendum to "Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells" [Toxicol. Lett. 179 (June(2)) (2008) 63-70] (DOI:10.1016/j.toxlet.2008.04.004);Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells

Toxicology Letters

Volumn 179, Issue 2, 2008, Pages 63-70

  Chiu, Shu Jun ^a   Chao, Jui I ^a   Lee, Yi Jang ^b   Hsu, Tzu Sheng ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Colorectal cancer cells; Oxaliplatin; p38 MAP kinase; Securin; H2AX

Indexed keywords

BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; HISTONE; MITOGEN ACTIVATED PROTEIN KINASE P38; OXALIPLATIN; PROTEIN GAMMA H2AX; SECURIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

EID: 44449170822     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.07.012     Document Type: Erratum

References (54)

1. Banath J.P., and Olive P.L. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res. 63 (2003) 4347-4350
2. Bernal J.A., Roche M., Mendez-Vidal C., Espina A., Tortolero M., and Pintor-Toro J.A. Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin. Cell Death Differ. 15 (2008) 202-212
3. Boelaert K., McCabe C.J., Tannahill L.A., Gittoes N.J., Holder R.L., Watkinson J.C., Bradwell A.R., Sheppard M.C., and Franklyn J.A. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 88 (2003) 2341-2347
4. Chamaon K., Kirches E., Kanakis D., Braeuninger S., Dietzmann K., and Mawrin C. Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes. Biochem. Biophys. Res. Commun. 331 (2005) 86-92
5. Chao J.I., Hsu S.H., and Tsou T.C. Depletion of securin increases arsenite-induced chromosome instability and apoptosis via a p53-independent pathway. Toxicol. Sci. 90 (2006) 73-86
6. Chiu S.J., Hsu T.S., and Chao J.I. Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells. Toxicol. Lett. 167 (2006) 122-130
7. Deacon K., Mistry P., Chernoff J., Blank J.L., and Patel R. p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol. Biol. Cell 14 (2003) 2071-2087
8. Dominguez A., Ramos-Morales F., Romero F., Rios R.M., Dreyfus F., Tortolero M., and Pintor-Toro J.A. hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 17 (1998) 2187-2193
9. Donzelli E., Carfi M., Miloso M., Strada A., Galbiati S., Bayssas M., Griffon-Etienne G., Cavaletti G., Petruccioli M.G., and Tredici G. Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J. Neurooncol. 67 (2004) 65-73
10. Downey M., and Durocher D. gamma H2AX as a Checkpoint Maintenance Signal. Cell Cycle 5 (2006) 1376-1381
11. Faivre S., Chan D., Salinas R., Woynarowska B., and Woynarowski J.M. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem. Pharmacol. 66 (2003) 225-237
12. Funabiki H., Yamano H., Kumada K., Nagao K., Hunt T., and Yanagida M. Cut2 proteolysis required for sister-chromatid seperation in fission yeast. Nature 381 (1996) 438-441
13. Goldberg M., Stucki M., Falck J., D'Amours D., Rahman D., Pappin D., Bartek J., and Jackson S.P. MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 421 (2003) 952-956
14. Gourdier I., Crabbe L., Andreau K., Pau B., and Kroemer G. Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 23 (2004) 7449-7457
15. Halicka H.D., Huang X., Traganos F., King M.A., Dai W., and Darzynkiewicz Z. Histone H2AX phosphorylation after cell irradiation with UV-B: relationship to cell cycle phase and induction of apoptosis. Cell Cycle 4 (2005) 339-345
16. Hamid T., and Kakar S.S. PTTG/securin activates expression of p53 and modulates its function. Mol. Cancer 3 (2004) 18
17. Heaney A.P., Nelson V., Fernando M., and Horwitz G. Transforming events in thyroid tumorigenesis and their association with follicular lesions. J. Clin. Endocrinol. Metab. 86 (2001) 5025-5032
18. Heaney A.P., Singson R., McCabe C.J., Nelson V., Nakashima M., and Melmed S. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355 (2000) 716-719
19. Hsiao P.W., Chang C.C., Liu H.F., Tsai C.M., Chiu T.H., and Chao J.I. Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicol. Appl. Pharmacol. 222 (2007) 97-104
20. Jallepalli P.V., Waizenegger I.C., Bunz F., Langer S., Speicher M.R., Peters J.M., Kinzler K.W., Vogelstein B., and Lengauer C. Securin is required for chromosomal stability in human cells. Cell 105 (2001) 445-457
21. Kakar S.S., and Jennes L. Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis. Cytogenet. Cell Genet. 84 (1999) 211-216
22. Kakar S.S., and Malik M.T. Suppression of lung cancer with siRNA targeting PTTG. Int. J. Oncol. 29 (2006) 387-395
23. Keogh M.C., Kim J.A., Downey M., Fillingham J., Chowdhury D., Harrison J.C., Onishi M., Datta N., Galicia S., Emili A., Lieberman J., Shen X., Buratowski S., Haber J.E., Durocher D., Greenblatt J.F., and Krogan N.J. A phosphatase complex that dephosphorylates gamma H2AX regulates DNA damage checkpoint recovery. Nature 439 (2006) 497-501
24. Lu C., Zhu F., Cho Y.Y., Tang F., Zykova T., Ma W.Y., Bode A.M., and Dong Z. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol. Cell 23 (2006) 121-132
25. Motoyama N., and Naka K. DNA damage tumor suppressor genes and genomic instability. Curr. Opin. Genet. Dev. 14 (2004) 11-16
26. Mukherjee B., Kessinger C., Kobayashi J., Chen B.P., Chen D.J., Chatterjee A., and Burma S. DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. DNA Repair (Amst) 5 (2006) 575-590
27. Nagao K., Adachi Y., and Yanagida M. Separase-mediated cleavage of cohesin at interphase is required for DNA repair. Nature 430 (2004) 1044-1048
28. Paull T.T., Rogakou E.P., Yamazaki V., Kirchgessner C.U., Gellert M., and Bonner W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol. 10 (2000) 886-895
29. Pei L., and Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 11 (1997) 433-441
30. Pfleghaar K., Heubes S., Cox J., Stemmann O., and Speicher M.R. Securin is not required for chromosomal stability in human cells. PLoS Biol. 3 (2005) e416
31. Puri R., Tousson A., Chen L., and Kakar S.S. Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. Cancer Lett. 163 (2001) 131-139
32. Ramaswamy S., Ross K.N., Lander E.S., and Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33 (2003) 49-54
33. Raymond E., Faivre S., Woynarowski J.M., and Chaney S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 25 (1998) 4-12
34. Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., and Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol. 52 (1996) 1855-1865
35. Rogakou E.P., Nieves-Neira W., Boon C., Pommier Y., and Bonner W.M. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J. Biol. Chem. 275 (2000) 9390-9395
36. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., and Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273 (1998) 5858-5868
37. Romero F., Gil-Bernabe A.M., Saez C., Japon M.A., Pintor-Toro J.A., and Tortolero M. Securin is a target of the UV response pathway in mammalian cells. Mol. Cell. Biol. 24 (2004) 2720-2733
38. Romero F., Multon M.C., Ramos-Morales F., Dominguez A., Bernal J.A., Pintor-Toro J.A., and Tortolero M. Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res. 29 (2001) 1300-1307
39. Sedelnikova O.A., Pilch D.R., Redon C., and Bonner W.M. Histone H2AX in DNA damage and repair. Cancer Biol. Ther. 2 (2003) 233-235
40. Solbach C., Roller M., Fellbaum C., Nicoletti M., and Kaufmann M. PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 13 (2004) 80-81
41. Stemmann O., Zou H., Gerber S.A., Gygi S.P., and Kirschner M.W. Dual inhibition of sister chromatid separation at metaphase. Cell 107 (2001) 715-726
42. Stordal B., Pavlakis N., and Davey R. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat. Rev. 33 (2007) 347-357
43. Taneja N., Davis M., Choy J.S., Beckett M.A., Singh R., Kron S.J., and Weichselbaum R.R. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J. Biol. Chem. 279 (2004) 2273-2280
44. Tsai S.J., Lin S.J., Cheng Y.M., Chen H.M., and Wing L.Y. Expression and functional analysis of pituitary tumor transforming gene-1 [corrected] in uterine leiomyomas. J. Clin. Endocrinol. Metab. 90 (2005) 3715-3723
45. van Attikum H., and Gasser S.M. The histone code at DNA breaks: a guide to repair?. Nat. Rev. Mol. Cell Biol. 6 (2005) 757-765
46. Woynarowski J.M., Faivre S., Herzig M.C., Arnett B., Chapman W.G., Trevino A.V., Raymond E., Chaney S.G., Vaisman A., Varchenko M., and Juniewicz P.E. Oxaliplatin-induced damage of cellular DNA. Mol. Pharmacol. 58 (2000) 920-927
47. Xie A., Puget N., Shim I., Odate S., Jarzyna I., Bassing C.H., Alt F.W., and Scully R. Control of sister chromatid recombination by histone H2AX. Mol. Cell 16 (2004) 1017-1025
48. Yamamoto A., Guacci V., and Koshland D. Pds1p, an inhibitor of anaphase in budding yeast, plays a critical role in the APC and checkpoint pathway(s). J. Cell Biol. 133 (1996) 99-110
49. Yu R., Heaney A.P., Lu W., Chen J., and Melmed S. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J. Biol. Chem. 275 (2000) 36502-36505
50. Yu R., Lu W., Chen J., McCabe C.J., and Melmed S. Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology 144 (2003) 4991-4998
51. Zhang X., Horwitz G.A., Heaney A.P., Nakashima M., Prezant T.R., Bronstein M.D., and Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 84 (1999) 761-767
52. Zhang X., Horwitz G.A., Prezant T.R., Valentini A., Nakashima M., Bronstein M.D., and Melmed S. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 13 (1999) 156-166
53. Zhou Y., Mehta K.R., Choi A.P., Scolavino S., and Zhang X. DNA damage-induced inhibition of securin expression is mediated by p53. J. Biol. Chem. 278 (2003) 462-470
54. Zou H., McGarry T.J., Bernal T., and Kirschner M.W. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285 (1999) 418-422